topic covers product, technologies, and basic research designed to produce a therapeutic, diagnostic or other function in healthcare, alone or in combination with other technologies.
The market for tissue engineering and cell therapy products is set to grow to nearly $32 billion by 2018. This figure includes bioengineered products that are themselves cells or are actively stimulating cell growth or regeneration, products that often represent a combination of biotechnology, medical device and pharmaceutical technologies. The largest segment in the overall [...]
Positive results were reported in January 2010 for a GenVec-sponsored trial in which researchers injected gene encoding for tumor necrosis factor-alpha (TNF-alpha) directly into tumors. This led to pathologic complete responses in one-third of the 24 esophageal cancer patients; the median survival was four years. Patients who received the three lowest does of TNF had [...]
The subject of "tissue engineering and cell therapy" is, by some accounts, an artificial amalgam of the two separate subjects, particularly since cell therapy per se, as a result of its inextricable link to embryonic stem cells and abortion, seems to demand (at least by some) a wholly separate consideration. From a scientific basis, of [...]
Cellular therapeutics with neurology applications currently encompass the entire range of development from preclinicals to approved, commercially available products in use. See the specific selected neurology cell therapy products on the market or in development by companies in the market: Personalized stem cell therapies for tissue regeneration Cell treatment for amyotropic lateral sclerosis Biopharmaceutical for [...]
Worldwide sales of cell therapy and tissue engineering products eclipsed $6.9 billion in 2009 on pace to reach $32 billion by 2018. This figure includes bioengineered products that are themselves cells or are actively stimulating cell growth or regeneration, products that often represent a combination of biotechnology, medical device and pharmaceutical technologies. The largest segment [...]
(Below is an excerpt from “Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018″, Report #S520.) Experts believe that stem cell therapy has the potential to treat a broad range of acute and chronic degenerative diseases. These applications include: hematopoietic cells for blood diseases and cancer, myocardial and endothelial vascular tissue [...]
(See published press release at link.) The use of stem cells, allografts, autografts and other cell and tissue types for the treatment of disorders and conditions has succeeded from a clinical standpoint for their ability to be rapidly accepted by the human body and their specificity to the disease state. This has been most clearly [...]
The global market for tissue engineering and cell therapy products is set to more than quadruple from 2009 to 2018. Products in cell therapy and tissue engineering include includes bioengineered products that are themselves cells or are actively stimulating cell growth or regeneration, products that often represent a combination of biotechnology, medical device and pharmaceutical [...]
With the initial markets for cell therapy and tissue engineering being best represented by clinical applications in orthopedics and skin/integumentary, a sampling of technologies at various states of development within each is worth considering for insights into likely near-term market impact. Below are select technologies under development by companies in cell therapy and tissue engineering. [...]
Cell Therapy is defined as a process whereby new cells are introduced into tissue as a method of treating disease; the process may or may not include gene therapy. Forms of cell therapy can include: transplantation of autologous (from the patient) or allogeneic (from a donor) stem cells , transplantation of mature, functional cells, application [...]
Contact:
